High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients

Leukemia Research

Volumn 32, Issue 4, 2008, Pages 547-551

  Au, Wing Yan ^a   Leung, Anskar Y H ^a   Tse, Eric W C ^a   Cheung, Winnie W W ^a   Shek, Tony W H ^a   Kwong, Yok Lam ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Alemtuzumab; Reactivation; Tuberculosis

Indexed keywords

ALEMTUZUMAB; ARSENIC TRIOXIDE; AZATHIOPRINE; CHLORAMBUCIL; CIPROFLOXACIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; EPIRUBICIN; ETHAMBUTOL; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; ISONIAZID; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PROCARBAZINE; PYRAZINAMIDE; RIFAMPICIN; VINCRISTINE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHINESE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CYTOPENIA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDEMIC DISEASE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HEMATOLOGIC MALIGNANCY; HONG KONG; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LYMPHATIC LEUKEMIA; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MALE; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SIDE EFFECT; T CELL LYMPHOMA; TUBERCULOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HONG KONG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUBERCULOSIS;

EID: 39049134275     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.06.010     Document Type: Article

References (26)

1. Moreton P., and Hillmen P. Alemtuzumab therapy in B-cell lymphoproliferative disorders. Semin Oncol 30 4 (2003) 493-501
2. Dearden C.E., and Matutes E. Alemtuzumab in T-cell lymphoproliferative disorders. Best Pract Res Clin Haematol 19 4 (2006) 795-810
3. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 10 2 (2005) 79-93
4. Cheung W.W., Hwang G.Y., Tse E., and Kwong Y.L. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica 91 5 Suppl (2006) [ECR13]
5. Martin S.I., Marty F.M., Fiumara K., Treon S.P., Gribben J.G., and Baden L.R. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43 1 (2006) 16-24
6. Thursky K.A., Worth L.J., Seymour J.F., Miles Prince H., and Slavin M.A. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 132 1 (2006) 3-12
7. Hui C.K., Cheung W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131 1 (2006) 59-68
8. Kaufmann S.H. How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol 1 1 (2001) 20-30
9. Boom W.H., Canaday D.H., Fulton S.A., Gehring A.J., Rojas R.E., and Torres M. Human immunity to M. tuberculosis: T cell subsets and antigen processing. Tuberculosis (Edinb) 83 1-3 (2003) 98-106
10. Fabian I., Flidel O., Gadish M., Kletter Y., Slavin S., and Nagler A. Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils. Exp Hematol 21 12 (1993) 1522-1527
11. Cheung W.W., Tse E., Leung A.Y., Yuen K.Y., and Kwong Y.L. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. Am J Hematol 82 2 (2007) 108-111
12. Au W.Y., Cheng V.C., Ho P.L., Yuen K.Y., Hung I., Ma S.Y., et al. Nontuberculous mycobacterial infections in Chinese hematopoietic stem cell transplantation recipients. Bone Marrow Transplant 32 7 (2003) 709-714
13. Yuen K.Y., Chan K.S., Chan C.M., Ho B.S., Dai L.K., Chau P.Y., et al. Use of PCR in routine diagnosis of treated and untreated pulmonary tuberculosis. J Clin Pathol 46 4 (1993) 318-322
14. Au W.Y., Lam C.C., Chim C.S., Pang A.W., and Kwong Y.L. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res 29 10 (2005) 1213-1215
15. Geng E., Kreiswirth B., Burzynski J., and Schluger N.W. Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. JAMA 293 22 (2005) 2740-2745
16. Wong K.H., and Lee S.S. Comparing the first and second hundred AIDS cases in Hong Kong. Singapore Med J 39 6 (1998) 236-240
17. Lui S.L., Tang S., Li F.K., Choy B.Y., Chan T.M., Lo W.K., et al. Tuberculous infection in southern Chinese renal transplant recipients. Clin Transplant 18 6 (2004) 666-671
18. Yuen K.Y., and Woo P.C. Tuberculosis in blood and marrow transplant recipients. Hematol Oncol 20 2 (2002) 51-62
19. Au W.Y., Kwong Y.L., Ma S.K., Mak Y.K., Wong K.F., Lei K.I., et al. Hairy cell leukemia in Hong Kong Chinese: a 12-year retrospective survey. Hematol Oncol 18 4 (2000) 155-159
20. Rezvany M.R., Tehrani M.J., Karlsson C., Lundin J., Rabbani H., Osterborg A., et al. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 135 4 (2006) 475-485
21. Wendtner C.M., Ritgen M., Schweighofer C.D., Fingerle-Rowson G., Campe H., Jager G., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18 6 (2004) 1093-1101
22. Abad S., Gyan E., Moachon L., Bouscary D., Sicard D., Dreyfus F., et al. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration. Clin Infect Dis 37 2 (2003) e27-e28 [Epub July 9, 2003]
23. Peleg A.Y., Husain S., Kwak E.J., Silveira F.P., Ndirangu M., Tran J., et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 44 2 (2007) 204-212
24. Weinblatt M.E., Maddison P.J., Bulpitt K.J., Hazleman B.L., Urowitz M.B., Sturrock R.D., et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum 38 11 (1995) 1589-1594
25. Lundin J., Hagberg H., Repp R., Cavallin-Stahl E., Freden S., Juliusson G., et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101 11 (2003) 4267-4272 [Epub January 23, 2003]
26. O'Brien R.J., and Perriens J.H. Preventive therapy for tuberculosis in HIV infection: the promise and the reality. Aids 9 7 (1995) 665-673